Parent Project Muscular Dystrophy and Akashi Therapeutics hosted a webinar on March 27, 2017 to discuss HT-100 and next steps for the clinical program. Akashi CEO Marc Blaustein presented data from the previous clinical program of HT-100, discussed FDA’s recent decision to allow the clinical development of HT-100 to resume, and answered questions from the community.
by: Parent Project Muscular Dystrophy
